Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 3/2011

01-03-2011 | Original Article

Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression

Authors: V. Rabenda, O. Bruyère, J.-Y. Reginster

Published in: Osteoporosis International | Issue 3/2011

Login to get access

Abstract

Summary

Surrogate measures of fracture risk, such as effects on bone mineral density, may be of great interest to assess the efficacy of available osteoporosis treatments. Our results suggest that bone mineral density (BMD) changes cannot be used as a surrogate of anti-fracture efficacy, among patients receiving calcium, with or without vitamin D.

Introduction

The purpose of this study is to examine the association between changes in bone mineral density with reduction in the risk of fractures in patients receiving calcium with or without vitamin D.

Methods

We selected all randomized placebo-controlled clinical trials of calcium with or without vitamin D supplementation. To be included in this analysis, the studies were required to report both BMD (hip/proximal femur and/or lumbar spine) and the incidence of fractures. Meta-regression analyses were used to examine the associations of changes in BMD with reduction in risk of fracture over the duration of each study. The change in BMD was the difference between changes (from baseline) observed in the active treatment group and placebo group.

Results

A total of 15 randomized trials (n = 47,365) were identified, most of whom (77%) came from the Women’s Health Initiative trial. Results show that larger increases in BMD at the lumbar spine were not associated with greater reduction in fracture risk. Concerning hip BMD changes, we found a statistically significant relationship between hip BMD changes and reduction in risk. However, results were not quite significant after excluding the both largest studies, in which BMD changes were measured in very small subset of patients. These points may have largely biased our results.

Conclusions

In conclusion, there was no evidence of a relationship between BMD changes and reduction in risk of fractures among patients receiving calcium with or without vitamin D supplementation. Calcium and/or Vitamin D may reduce fracture rates through a mechanism independent of bone density.
Literature
1.
2.
Temple RJ (1995) A regulatory authority’s opinion about surrogate endpoints. In: Nimmo WS, Tucker GT (eds) Clinical measurement in drug evaluation. Wiley, New York
3.
Li Z, Chines AA, Meredith MP (2004) Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture? J Musculoskelet Neuron Interact 4:6474
4.
Bouxsein ML, Delmas PD (2008) Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res 23:1155–1167CrossRefPubMed
5.
Boonen S, Body JJ, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman JM, Rozenberg S, Reginster JY (2005) Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 16:239–254CrossRefPubMed
6.
Rizzoli R, Boonen S, Brandi ML, Burlet N, Delmas P, Reginster JY (2008) The role of calcium and vitamin D in the management of osteoporosis. Bone 42:246–249CrossRefPubMed
7.
Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A (2007) Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370:657–666CrossRefPubMed
8.
Jadad AR, Moore RA, Carroll D, Jenkinson C (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12CrossRefPubMed
9.
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101CrossRefPubMed
10.
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple graphical test. BMJ 315:629–634PubMed
11.
Hatal R, Keitz S, Wyer P, Guyatt G, on behalf of the Evidence-Based Medicine Teaching Tips Working Group (2005) Tips for learners of evidence-based medicine: 4. Assessing heterogeneity of primary studies in systematic reviews and whether to combine their results. CMAJ 172:661–665
12.
Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ (1993) Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 328(7):460–464CrossRefPubMed
13.
Chevalley T, Rizzoli R, Nydegger V, Slosman D, Rapin CH, Michel JP, Vasey H, Bonjour JP (1994) Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients. Osteoporos Int 4:245–252CrossRefPubMed
14.
Riggs BL, O’Fallon WM, Muhs J, O’Connor MK, Kumar R, Melton LJ 3rd (1998) Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. J Bone Miner Res 13:168–174CrossRefPubMed
15.
Peacock M, Liu G, Carey M, McClintock R, Ambrosius W, Hui S, Johnston CC (2000) Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab 85:3011–3019CrossRefPubMed
16.
Fujita T, Ohue M, Fujii Y, Miyauchi A, Takagi Y (2004) Reappraisal of Katsuragi calcium study, a prospective, double-blind, placebo-controlled study of the effect of active absorbable algal calcium (AAACa) on vertebral deformity and fracture. J Bone Miner Metab 22(1):32–38CrossRefPubMed
17.
Reid IR, Mason B, Horne A, Ames R, Reid HE, Bava U, Bolland MJ, Gamble GD (2006) Randomized controlled trial of calcium in healthy older women. Am J Med 119:777–785CrossRefPubMed
18.
Prince RL, Devine A, Dhaliwal SS, Dick IM (2006) Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med 166:869–875CrossRefPubMed
19.
Reid IR, Ames R, Mason B, Reid HE, Bacon CJ, Bolland MJ, Gamble GD, Grey A, Horne A (2008) Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men. Arch Intern Med 168(20):2276–2282CrossRefPubMed
20.
Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas P, Meunier PJ (1992) Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327:1637–1642CrossRefPubMed
21.
Dawson-Hughes B, Harris S, Krall E, Dallal G (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337:670–676CrossRefPubMed
22.
Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, Garnero P, Meunier PJ (2002) Combined calcium and vitamin D3 supplementation in elderly women:confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 13:257–264CrossRefPubMed
23.
Harwood RH, Sahota O, Gaynor K, Masud T, Hosking DJ (2004) A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: the Nottingham Neck of Femur (NoNOF). Study Age Ageing 33(1):45–51CrossRef
24.
Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Women’s Health Initiative Investigators et al (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669–683CrossRefPubMed
25.
Bolton-Smith C, McMurdo ME, Paterson CR, Mole PA, Harvey JM, Fenton ST, Prynne CJ, Mishra GD, Shearer MJ (2007) Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women. J Bone Miner Res 22(4):509–519CrossRefPubMed
26.
Salovaara K, Tuppurainen M, Kärkkäinen M, Rikkonen T, Sandini L, Sirola J, Honkanen R, Alhava E, Kröger H (2010) Effect of vitamin D3 and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial—The OSTPRE-FPS. JBMR 25:1487–1495CrossRef
27.
Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD (2002) Relationships between bone mineral density and incident vertebral fractures with raloxifene therapy. J Bone Miner Res 17:1–10CrossRefPubMed
28.
Watts NB, Cooper C, Lindsay R et al (2004) Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7:255–261CrossRefPubMed
29.
Li Z, Meredith MP, Hoseyni MS (2001) A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 20:3175–3188CrossRefPubMed
30.
Hochberg MC, Ross PD, Black D, Fracture Intervention Trial Research Group et al (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 42:1246–1254CrossRefPubMed
31.
Bruyère O, Roux C, Badurski J et al (2007) Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 23:3076–3081
32.
Wasnich RD, Miller PD (2000) Antifracture efficacy with antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231–236CrossRefPubMed
33.
Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281–289CrossRefPubMed
34.
Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586–1592CrossRefPubMed
35.
Delmas PD, Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral and nonvertebral fracture risk with anti-resorptive therapy. Bone 34:599–604CrossRefPubMed
36.
Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, The Fracture Intervention Trial Study Group et al (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250–1258CrossRefPubMed
37.
38.
39.
National Osteoporosis Foundation. New clinicians guide to prevention and treatment of osteoporosis. Available at: www.​nof.​org
40.
Thompson S, Higgins J (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21:1559–1573CrossRefPubMed
41.
Lambert P, Sutton A, Abrams F et al (2002) A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol 55:86–94CrossRefPubMed
Metadata
Title
Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression
Authors
V. Rabenda
O. Bruyère
J.-Y. Reginster
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 3/2011
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-010-1469-x

Other articles of this Issue 3/2011

Osteoporosis International 3/2011 Go to the issue

Original Article

Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study

Original Article

Development and validation of a disease model for postmenopausal osteoporosis

Original Article

Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective

Review

Effects of therapeutic exercise for persons with osteoporotic vertebral fractures: a systematic review

Original Article

Oral bisphosphonates are associated with reduced mortality after hip fracture

Original Article

Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study